Background: In patients with Type 2 Diabetes (DT2), arterial hypertension (HTN) is twice more frequent. Coexistence of HTN and DT2 increases the risk of coronary artery disease (CAD), heart failure (HF), cerebrovascular accident (CVA), cardiovascular disease mortality (CVD), and the risk of nephropathy, retinopathy and neuropathy. Blood pressure (BP) control reduces the rate of DT2 complications. Objectives: Quantify the frequency of HTN in patients with DT2 in Argentina. Know the rate that achieves the BP goal and identify the factors related to higher and lower levels of the goal. Determine therapeutic tools and adherence to treatment. Materials and Method: A descriptive, observational, cross-sectional, multicenter study was designed in 28 centers in Argentina specialized in Diabetes (FRADYC III Group). Patients older than 18 years with DT2 were included. Medical history, clinical examination, laboratory, complications, cardiovascular risk factors and HTN medication were considered. BP target was < 140/90 mmHg. Morisky-Green-Levine test was used to evaluate adherence and the WHO 5 test for quality of life (low well-being less than 50 points). STATA intercooler software. Results: In 1329 patients with DT2, women 46.6%, mean age 61.7 ± 11.6 years, with mean HbA1c 7.0 ± 1.4%, age of DM2 9.6 ± 7.4 years, BMI 31.7 ± 5.7 kg/m2, with waist circumference (WC) > 88 cm in women and > 102 cm in men 76.7%, HTN 81%, during 12.7 ± 9.4 yrs, dyslipidemia (DLP) 81.4%, CVD 37.2%, neuropathy 19%, nephropathy 12.6%, retinopathy 10%, depression 11.7%, smoked 11.6% and physical activity ≥ 150 minutes/week 29.8%. Adherence to treatment was 68.37%, with low well-being 21%. Treatment of HTN: no drugs 9.9%, 1 drug 42.9%, 2 drugs 29.6%, and 3 or more drugs 14.2%. HTN drugs were: ARA II 35%, ACEI 31.9%, cardioselective beta-blockers 19.5%, amlodipine 14.6%, thiazides 12.7%, non-cardioselective beta-blocker 6%, loop diuretics 3.2%, indapamide 2%, spironolactone 1.7%, nifedipine 0.9%. The goal was achieved by 62.4% of DT2 with HTN with no differences by age or gender. The older, more than 65 years (p = 0.0001) the greater the adherence to treatment. Reaching the goal was associated with less HTN time (p = 0.0091), higher education (p = 0.0001), private insurance (p = 0.0001), physical activity (p = 0.028), no nephropathy (p = 0.010), and no neuropathy (p = 0.023). Lower achievement no HTN drugs (p = 0.0001) and low well-being (p = 0.027). Multiple logistic regression: reaching the goal was associated with no cardiometabolic risk waist (OR: 0.67, p = 0.021), no nephropathy (OR: 0.69, p = 0.045), and private insurance (OR: 1.9, p = 0.0001). Conclusions: In this study, 81% of DT2 patients had HTN, well controlled in 62.4%. Higher education, physical activity, private insurance, and HTN drug treatment were associated with BP goal, while abdominal obesity, nephropathy, no health insurance, not taking HTN medications and less well-being had a negative association. The youngest, despite less adherent and with shorter HTN time, reached the goal with the same statistical significance as the older ones. We should assess welI-being and optimize adherence in the youngest.